Last month, the company disclosed its financial report for the fiscal year ended December 31, 2010 and there was a statement there that ELGO is listed on the OTCBB, but the company’s common stock has never been traded.

Since this Monday, three stock promoters have come to support and increase the demand for the company’s shares. Though the promotional budget of sixty thousand dollars may not be enough for a not very popular stock, ELGO proved to have potential to rise and to attract investors.

Looks like ELGO succeeded to win investors’ confidence with the press release presenting the company’s business model.

In its recently disclosed prospectus supplement update, Enterologics Inc. offers on the best efforts basis up to 32,500,000 shares at a price of $0.05 per share. At the same time, during yesterday’s trading session, ELGO was traded within the range of $0.44 – $0.50 per share.

It is a courageous decision of the company to make the above offering without the involvement of any underwriters or broker-dealers. ELGO even states that the shares will be sold by the company’s executive officers and directors and without any compensation or commission on the proceeds from the sale.

Maybe this was also one of the reasons for the high investor appreciation towards ELGO these days.

The other conceivable reason could be that yesterday the fair, according to investors, market value of Enterologics Inc. reached $12.77 million. The development-stage company has no significant assets, but for the fiscal year end it reports a net loss of $80.7 thousand and a negative cash flow from operations of $58.1 thousand since its inception in 2009.[BANNER]

The business model of Enterologics Inc. is to generate revenues from the sale of pro-biotic, bio-therapeutic drug products.

At present, Enterologics Inc. is focused on the license agreement with Universal Stabilization Technologies, Inc. (UST), a Delaware company, for the exclusive worldwide license of UST’s intellectual property. It is related to the preservation/stabilization of Escherichia coli pro-biotic bacteria and the protection of the company’s use of E. coli bacteria as a pro-biotic.

ELGO plans to enter into a one-year development agreement with UST prior to the middle of May. Yesterday, investors appreciated the rapid upward move of the company’s shares, knowing the company’s program. Now, it remains to expect positive news in a few weeks.

Go here to see the original:

UNDT came out with fresh news today and the stock gapped higher opening at the high of the session and trading between $.0026 and $.0019 the rest of the day. Tomorrow it will be interesting to see if this stock can hold its gains from today. Last time we saw news for this stock it sold of in the following sessions

View original post here:
UNDT – More News Today Bolsers The Stock

Read more from the original source:
Human Genome Sciences (HGSI) Reaches Agreement with FivePrime for Cancer Drug

Read more from the original source:
Starbucks (SBUX) and Green Mountain (GMCR) Agree to Sell K-Cups

Yesterday, IceWEB, Inc. (OTC:IWEB) announcement that it could grow its sales almost 30 times in the coming year through a merger agreement made its stock do what it could not do in the last months despite all the numerous promotions and positive announcements. IWEB gapped up on tremendous volume and no recent resistances for the share price were left unbroken.

IWEB closed the market at $0.25, 28.21% higher than the previous close and traded over 2.6 million shares for the day. Apart from the running stock promotions, the company’s registration statement for 26 million new shares of common stock got also declared effective by the SEC last month. In addition, IWEB filed its latest 10-Q report.

However, those were all events not considered that spectacular by traders, as it is questionable if the observed increase in the value of the stock last month would have happened without the paid promoters. Now, it looks like yesterday the event that could, according to many investors, justify the current market cap and provide future potential got finally revealed.

As promised on Friday afternoon, IceWEB announced a significant material event: the company has reached a definitive merger agreement with Promark Technology, Inc., a private distributor of data storage products and solutions. The press release sounds promising, but if the merger would actually change something for IWEB shareholders depends on the projected “immediate and dramatic improvement” in the company’s revenues, profits and market share resulting from the new agreement.

In the case of IceWEB, it is hard to speak about profits at this point, as it has been losing money in millions over the last three years. The company has also a working capital deficit to cover and debts exceeding the assets.

Moreover, it looks like it will not be possible for IceWEB to pay in cash its obligation under the agreement with its $256,000 available as of December 31, 2010. The corresponding SEC filing confirming the merger agreement reveals that pursuant to the terms of the transaction IceWEB will pay the selling shareholders total consideration of $10.78 million, for expected additional $100 million in revenues in the coming year.

Read the original here:

Diadem Resources Limited (CVE:DRL) (PINK:DRLFF) stock price recorded a 44% jump in price as the company filed a quarterly report.

The share price jumped after the company filed their interim financial report for the quarter ended November 30, 2010.

The quarterly report shows that:

• Outstanding share count more than doubled over the last year
• Net loss increased nearly 4 times, due to active business management related jump in expenses
• Diadem requires additional cash to continue exploration programs
• DRL is committed to spend $2 million on the Franklin Project before June 30, 2011, under a cooperation agreement with Darnley Bay Resources.

The update might hold back the share price depreciation for a bit, possibly by causing a consolidation period. However, considering the company disclosed a lack of working capital, shareholders should be aware that more dilution is likely underway.

The latest funding round of similar proportion, done in July 2010, only caused volatility on the market and the price continued to decline steadily afterward. It might be slightly different when the company tries to raise the required $2 million over the coming half a year. Trading volume, which was recorded upon the filing of the quarterly report, shows an increase in attention the stock gets.

The market cap is currently at $5.3 million, 1.35 times the net tangible worth of the company, so there is a considerable upside potential if the company manages to raise the cash.

Read the original:

The strongest trading volume recorded for FLTT is the only thing different from the other short rallies. The stock is not worth to hold higher values as the company is in a seriously adverse financial situation:[BANNER]

• Decreasing revenues;
• Miniscule gross profit margin;
• Continuous large net losses;
• Very heavily leveraged balance sheet;
• Virtually no cash or other liquid assets;
• Losses continue to be covered with borrowed capital.

Based on the continuing deterioration of the fundamentals, stock price will likely remain on the downtrend, slowly declining after each and every correction. The bottom is still far from being found, and increases in trading volume are likely the cause of the decreasing price, not the increasing interest from traders.

Flint is seriously threatened with bankruptcy. The business has recently announced a stock purchase agreement with Kodiak Capital Group, LLC, under which the company will be able to sell $15 million worth of shares. This means even more dilution to shareholders, providing only temporary financial relief for the troubled business.

Here is the original post:

After the 40% gain on Monday, Conspiracy Entertainment Holdings Inc (OTC:CPYE) is already falling down, while its traded volume remains very impressive. Yesterday, CPYE lost 6.83% of its market price and the volume exceeded 3 million shares traded.

Apparently, investors’ encouragement didn’t last for long and they started dumping their shares.

This fact looks quite astonishing, following the latest news about Conspiracy Entertainment. Over the past week, the company has published positive announcements about its business and the latest one came up just yesterday.

According to it, CPYE has entered into a distribution agreement with Fillpoint SVG Distribution, Inc. for

The two day rally, which occurred by the end of the last week, was created when the company signed a partnership agreement with a European Institute of Microbiology. The new partners agreed to manufacture A5′s interferon products using the technology provided by the company.

News can be taken controversially – it’s good that the company finally found a way to produce interferon products without a need to lay down heavy investment and build their own facilities. On the other hand, no material changes have taken place, and the effectiveness of the products remains as questionable as it was before the company partnered with Institute of Microbiology.[BANNER]

The products are still in research, and manufacturing will only be required for the in-vitro and in-vivo studies, not the commercial production.

A5 Laboratories struggles financially, thus the partnership agreements are essential for this micro cap company.

The stock has been dwelling low for the past half a month, finding support near the $0.40 level. The news got the price bouncing, but the volume appears too weak to trigger anything more than a couple days rally.

Visit link:

As the news about the private placement was confirmed through the corresponding 8-k filing on Friday, the trend of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares getting oversold finally reversed.

Raptor’s stock jumped 15.20% up on Friday and closed the trading session at $2.88 for a share. Nearly 800,000 shares of the stock were traded, a value almost four time the average and expressing the positive attitude of investors, who may finally expect a break through after the four months of sideways moves. Though, as the previous resistances remained untouched, it is probably too early to get too excited.

According to the filing on Friday, the company has entered into a securities purchase agreement with certain US and Canadian investors for the private placement of RPTP units, each unit consisting of one share and one warrant to purchase one share of common stock. The offering was closed on Thursday, whereby around 4.9 million units were issued for gross proceeds of $15 million, or the price for one unit was $3.075. It seems that the dilution will happen soon, as the company took also the obligation to file a registration statement for the securities already issued or still up to be issued upon the exercise of the warrants.

Raptor’s stock reached its current levels with several sharp jumps up in the beginning of May, as one of the latest important corporate updates was announced, namely the positive clinical results in one of the company’s Phase 2a product candidates for the treatment of liver disease.

It seems that investors see a possible improvement in the liquidity as a positive consequence from the recent sales of common stock, along with the negative one from the expected dilution.

In April this year, the company signed a securities purchase agreement with an investment fund, according to which the investor agreed to purchase up to $15 million of the RPTP common stock over a 25 month period. Pursuant to that agreement, in the beginning of May a registration statement was filed, related to the sale of 4.5 million shares by that institutional investor.

Raptor Pharmaceutical is currently working on three clinical development programs and has another three for which the company is searching a development partner. At the end of June, a partner for one of that programs, ConviviaTM, has been found.

See the original post here: